



Advanced Cell Biology & Biotechnology



Biotechnology Project Lab



Giovanna Gambarotta
& Isabella Tarulli

The lecture is about to begin....


- Summary of the activity of the previous lesson
- Overview of the next lessons
- Welcome test
- RT-PCR for full length cloning or gene expression analysis

Identification of specific domains





3' end of the EGF-like domain + 5' end of the transmembrane domain





```

Query 661 CCTAAACTTTCCACATCAACATCCACGACTGGGACCAGCCATCTCATAAAGTGTGCGGAG 720
Sbjct 661 CCTAAACTTTCCACATCGACATCCACGACTGGGACCAGCCATCTCATAAAGTGTGCGGAG 720
Query 721 AAGGAGAAAACCTTTCTGTGTGAATGGGGGCGAGTGTCTTACGGTGAAGGACCTGTCAAAC 780
Sbjct 721 AAGGAGAAAACCTTTCTGTGTGAATGGGGGCGAGTGTCTTACGGTGAAGGACCTGTCAAAC 780
Query 781 CCGTCAAGATACTTGTGCAAGTGCC 805
Sbjct 781 CCGTCAAGATACTTGTGCAAGTGCC 805
    
```


Range 2: 884 to 2103 [Graphics](#) ▼ Next Match ▲ Previous Match ▲ First Match

Score	Expect	Identities	Gaps	Strand
2254 bits(1220)	0.0	1220/1220(100%)	0/1220(0%)	Plus/Plus
Query 869	AAGCGGAGGAACTCTACCAGAAGAGGGTGTCTGACAATTACTGGCATCTGTATCGCCCTGC	928		
Sbjct 884	AAGCGGAGGAACTCTACCAGAAGAGGGTGTCTGACAATTACTGGCATCTGTATCGCCCTGC	943		
Query 929	TGGTGGTCGGCATCATGTGTGTGGTGGCCTACTGCAAACCAGAAGCAGCGGCAGAAGC	988		
Sbjct 944	TGGTGGTCGGCATCATGTGTGTGGTGGCCTACTGCAAACCAGAAGCAGCGGCAGAAGC	1003		
Query 989	TTCATGATCGGCTTCGGCAGAGTCTTCGGTCAGAACGGAGCAACCTGGTGAACATAGCGA	1048		
Sbjct 1004	TTCATGATCGGCTTCGGCAGAGTCTTCGGTCAGAACGGAGCAACCTGGTGAACATAGCGA	1063		
Query 1049	ATGGGCCTCACCACCCAAACCCGCCGCCAGAGAACGTGCAGCTGGTGAATCAATACGTAT	1108		

5' and 3' ends of the EGF-like domain



5' and 3' ends of the EGF-like domain




Score	Expect	Identities	Gaps	Strand
241 bits(130)	1e-66	134/136(99%)	0/136(0%)	Plus/Plus
Query 916	TCCACATCGACATCCACGACTGGGACCAGCCATCTCATAAAGTGC GCGGAGAAGGAGAAA	975		
Sbjct 670	TCCACATCAACATCCACGACTGGGACCAGCCATCTCATAAAGTGTGC GCGGAGAAGGAGAAA	729		
Query 976	ACTTTCTGTGTGAATGGGGGCGAGTGCTTCACGGTGAAGGACCTGTCAAACCCGTCAAGA	1035		
Sbjct 730	ACTTTCTGTGTGAATGGGGGCGAGTGCTTCACGGTGAAGGACCTGTCAAACCCGTCAAGA	789		
Query 1036	TACTTGTGCAAGTGCC 1051			
Sbjct 790	TACTTGTGCAAGTGCC 805			

Range 2: 869 to 2088 [Graphics](#)

[Next Match](#) [Previous Match](#) [First Match](#)

Score	Expect	Identities	Gaps	Strand
2254 bits(1220)	0.0	1220/1220(100%)	0/1220(0%)	Plus/Plus
Query 1130	AAGCGGAGGAACTCTACCAGAAGAGGGTGCTGACAATTACTGGCATCTGTATCGCCCTGC	1189		
Sbjct 869	AAGCGGAGGAACTCTACCAGAAGAGGGTGCTGACAATTACTGGCATCTGTATCGCCCTGC	928		
Query 1190	TGGTGGTCGGCATCATGTGTGTGGTGGCCTACTGCAAAACCAAGAAGCAGCGGCAGAAAGC	1249		
Sbjct 929	TGGTGGTCGGCATCATGTGTGTGGTGGCCTACTGCAAAACCAAGAAGCAGCGGCAGAAAGC	988		
Query 1250	TTCATGATCGGCTTCGGCAGAGTCTTCGGTCAGAACGGAGCAACCTGGTGAACATAGCGA	1309		
Sbjct 989	TTCATGATCGGCTTCGGCAGAGTCTTCGGTCAGAACGGAGCAACCTGGTGAACATAGCGA	1048		
Query 1310	ATGGGCCTCACCACCCAAACCCGCCGCCAGAGAACGTGCAGCTGGTGAATCAATACGTAT	1369		
Sbjct 1049	ATGGGCCTCACCACCCAAACCCGCCGCCAGAGAACGTGCAGCTGGTGAATCAATACGTAT	1108		




I- α 2c		U02324 (rat)
I- β 4a		U02322 (rat)
II- β 1a		AF194993 (rat)
III- α 2a		AF194439 (rat)
III- β 1a		AF194438 (rat)
III- β 3		DQ176766.1 (rat)

5' and 3' end of the EGF-like domain

Query
Sbjct

III-β3

I-α2c



DQ176766.1 (rat)

U02324 (rat)

Query	670	TCCACATCAACATCCACGACTGGGACCAGCCATCTCATAAAAGTGTGCGGAGAAGGAGAAA	729
Sbjct	502	TCCACATCAACATCCACGACTGGGACCAGCCATCTCATAAAAGTGTGCGGAGAAGGAGAAA	561
Query	730	ACTTTCTGTGTGAATGGGGGCGAGTGCTTCACGGTGAAGGACCTGTCAAACCCGTCAAGA	789
Sbjct	562	ACTTTCTGTGTGAATGGGGGCGAGTGCTTCACGGTGAAGGACCTGTCAAACCCGTCAAGA	621
Query	790	TACTTGTGCAAGTGCC	805
Sbjct	622	TACTTGTGCAAGTGCC	637



- Oligo
- Sequence
 - U02324 NRG1 I alpha2c
 - U02322 NRG1 I beta4a
 - AF194993 NRG1 II beta1a
 - AF194439 NRG1 III-alpha2a
 - AF194438 NRG1 III-beta1a
 - DQ176766 NRG1 III-beta3
- Multiple alignment

Oligo | Oligo list | Sequence | Sequence list | Multi-alignment | Multi-alignment list

Name: Long name:

Description:

Length: Type: checksum: Author: Creation date:

Sequence header

Sequence annotations

Name	init	end	comments
type I	1	99	
EGF-like	502	637	
alpha	638	700	

```

1 atgtctgagc gcaagaagc cagaggcaag ggaaggcca agaagaagga
51 cgggggatcc cgcggaagc ccgggcccgc cgagggcgac ccgagcccaag
101 cactgcctcc cagattgaaa gaaatgaaga gccaggagtc agctgcaggc
151 tccaagctag tgctccggtg cgaaccagc tccgagtact cctcactcag
201 attcaaatgg ttcaagaatg ggaacgagct gaaccgcaa aataaaccag
251 aaaacatcaa gatacagaag aagccagga agtcagagct tcgaattaac
301 aaagcatccc tggctgactc tggagagtat atgtgcaaag tgatcagcaa
351 gttaggaat gacagtgcct ctgccaat caccattgtt gagtcaaacg
401 agttcatcac tggcatgcca gcctcgactg agacagccta tgtgtcctca
451 gagtctccca ttagaatctc agtttcaaca gaaggcgcaa acacttcttc
501 atccacatca acatccaaga ctgggaccag ccatctcata aagtgtggag
551 agaaggagaa aactttctgt ttgaaatgggg gcgagtgcct ccgggtgaag
601 gacctgtcaa acccgtcaag atacttgtgc aagtgcacac caggtattca
651 tggagcaaga tgtactgaga atgtaccat gaaagtccaa acccaagaaa
701 aagcggagga actctaccag aagagggtgc tgacaattac tggcatctgt
751 atcgccctgc tgggtgctcg catcatgtgt gtggtggcct actgcaaac
801 caagaagcag cggcagaagc ttcatgatcg gcttcggcag agtcttcggt
851 caaacgaa caacctata aacataacaa ataacctca ccaccaaac
    
```



- Oligo
- Sequence
 - U02324 NRG1 I alpha2c
 - U02322 NRG1 I beta4a**
 - AF194993 NRG1 II beta1a
 - AF194439 NRG1 III-alpha2a
 - AF194438 NRG1 III-beta1a
 - DQ176766 NRG1 III-beta3
- Multiple alignment

Oligo | Oligo list | Sequence | Sequence list | Multi-alignment | Multi-alignment list

Name Long name

Description

Length Type checksum Author Creation date


Sequence header

Sequence annotations

Name	init	end	comments
■ type I	1	99	
■ EGF-like	502	637	
■ beta	638	691	

```

1 atgtctgagc gcaaagaagc cagaggcaag ggaaggcca agaagaagg
51 cgggggatcc cgcggaagc cggggcccgc cgaggcgac ccgagccag
101 cactgcctcc cagattgaaa gaaatgaaga gccaggagtc agctgcaggc
151 tccaagctag tgctccggtg cgaaaccagc tccgagtact cctcactcag
201 attcaaatgg ttcaagaatg ggaacgagct gaaccgaaa aataaaccag
251 aaaacatcaa gatacagaag aagccaggga agtcagagct tcgaattaac
301 aaagcatccc tggctgactc tggagagtat atgtgcaaag tgatcagcaa
351 gttaggaaat gacagtgcct ctgccaatat caccattggt gagtcaaacg
401 agttcatcac tggcatgcca gcctcgactg agacagccta tgtgtcctca
451 gagtctccca ttagaatctc agtttcaaca gaaggcgcaa acacttcttc
501 atccacatca acatccacga ctgggaccag ccactctcata aagtgtgagg
551 agaaggagaa aactttctgt gtgaatgggg gcgagtgctt cagggtgaag
601 gacctgtcaa acccgtcaag atacttgtgc aagtgcccaa atgagtttac
651 tggtgatcgt tgccaaaact acgtaatggc cagcttctac atgacttcta
701 ggaggaaaag gcaagaaaca gagaagcctc tagaaagaaa attggatcat
751 agccttgtga aagaatcgaa agcggaggaa ctctaccaga agagggtgct
801 gacaattact ggcattctgta tcgccttgct ggtggtcggc atcatgtgtg
851 taataccta ctacaaaacc aaaaacacac acaaaaact tcataatcaa
    
```



- Oligo
- Sequence
 - U02324 NRG1 I alpha2c
 - U02322 NRG1 I beta4a
 - AF194993 NRG1 II beta1a**
 - AF194439 NRG1 III-alpha2a
 - AF194438 NRG1 III-beta1a
 - DQ176766 NRG1 III-beta3
- Multiple alignment

Oligo | Oligo list | **Sequence** | Sequence list | Multi-alignment | Multi-alignment list

Name: Long name:

Description:

Length: Type: checksum: Author: Creation date:

Sequence header:

Sequence annotations

Name	init	end	comments
type II	1	513	
EGF-like	918	1051	
beta	1052	1105	

```

101 aggcagcagg cgaggcaggg gcagggggcgc gggaccagcc cgtccaggac
151 tcgccacctt cacaggaccc tctgcctgct gtcaactgga ccttgcccac
201 tgggggcccc gagcccagca cogatcagcc cggggacccc gcgccctatc
251 tggtaaggtg gcaccaggtg tgggctgtga aagccggggg tttgaagaag
301 gactcgctac tcaccgtgcg cctggatacc tggggccacc cagccttccc
351 gtccctgcggg cggctcaagg aggacagcag gtacatcttc ttcattggagc
401 cggatgccaa cagcagcggc cgcgcgcgcg ccgccttcgg agcctcgttt
451 cccccactgg aactggcggc caacctcaag aaggaggcca gccgggtggt
501 gtgcaagcgg tgcgcactgc ctcccagatt gaaagaaatg aagagccagg
551 agtcagctgc aggtccaag ctatgtctcc ggtgcgaaac cagctccgag
601 tactcctcac tcagattcaa atggttcaag aatgggaacg agtgaaccg
651 caaaaataaa ccagaaaaca tcaagataca gaagaagcca ggaagtcag
701 agcttcgaat taacaaagca tccttggtg actctggaga gtatatgtgc
751 aaagtgatca gcaagttagg aatgacagt gcctctgcca acatcaccat
801 tgttgagtca aacgagttca tcaactggcat gccagcctcg actgagacag
851 cctatgtgtc ctcaagttct cccattagaa tctcagtttc aacagaaggc
901 gcaaacactt cttcattccac atcgacatcc acgactggga ccagccatct
951 cataaagtgc gcggagaagg agaaaacttt ctgtgtgaat gggggcgagt
1001 gcttcacggt gaaggacctg tcaaaccctt caagatactt gtgcaagtgc
1051 ccaaatgagt ttactgggta tcggttgccaa aactacgtaa tggccagctt
1101 ctacaagcat cttgggattg aatttatgga agcggaggaa ctctaccaga
    
```




- Oligo
- Sequence
 - U02324 NRG1 I alpha2c
 - U02322 NRG1 I beta4a
 - AF194993 NRG1 II beta1a
 - AF194439 NRG1 III-alpha2a**
 - AF194438 NRG1 III-beta1a
 - DQ176766 NRG1 III-beta3
- Multiple alignment

Oligo | Oligo list | **Sequence** | Sequence list | Multi-alignment | Multi-alignment list

Name Long name

Description

Length Type checksum Author Creation date

Sequence header

Sequence annotations

Name	init	end	comments
EGF-like domain	670	805	
exon alpha	806	888	
type III	1	689	

```

1 atggagattt attccccaga catgtctgag gtagctggcg ggaggtcctc
51 cagcccctcc actcagctga gtgcagttcc atctcttgat gggcttcggg
101 cagcggagga acatatacca gacacccaca cagaagatga gagaagcctc
151 ggactcctgg gcctggcggg gcctgctgtg gtgtgctggg aagctgagcg
201 cctgagaggg tgtctcaact ccgagaagat ctgcattggt cccattctgg
251 ctgocctagt cagcctctgc ctctgcattg ctggcctgaa gtgggtattt
301 gtggacaaga tatttgaata cgactctcct acccaccttg accctggggg
351 gtagggccag gaccctgtga tttctctgga tccaactgct gccccagcca
401 ttttggatc atccgaggca tacaactcac ctgtctctaa ggctcagctc
451 gaagctgggg ctcatgttac agtacaaggt gaccatgctg ctgtggcctc
501 tgaaccttca gcagtaccga ccggaagaa ccggctgtct gcttttctc
551 cctttcacc cactgcaccg cccttccctt ctccagctcg gaccctgag
601 gtgagaacac ccaagtcagg aactcagcca caaacaacag aaactaacct
651 gcaaaactgt cctaaacttc ccacatcaac atccaagact gggaccagcc
701 atctcataaa gtgtgctggg aaggagaaaa ctttctgtgt gaatgggggg
751 gagtgcttca cggatgaagg cctgtcaaac ccgtcaagat actgtgcaa
801 gtgccaacct ggattcactg gagcaagatg tactgagaat gtaccatgga
851 aagtccaaac ccaagaaaaa gggaggaac tctaccagaa gagggtgctg
901 acaattactg gcatctgtat cgccctgctg gtggctggca tcatgtgtgt
951 ggtggcctac tgcaaaacca agaagcagcg gcagaagctt catgatcggc
1001 ttgggcagag tcttcgggtc gaacggagca acctggtgaa catagcgaat
    
```



- Oligo
- Sequence
 - U02324 NRG1 I alpha2c
 - U02322 NRG1 I beta4a
 - AF194993 NRG1 II beta1a
 - AF194439 NRG1 III-alpha2a
 - AF194438 NRG1 III-beta1a**
 - DQ176766 NRG1 III-beta3
- Multiple alignment

Oligo Oligo list Sequence Sequence list Multi-alignment Multi-alignment list

Name Long name

Description

Length Type checksum Author Creation date


Sequence header

Sequence annotations

Name	init	end	comments
beta	808	859	
type III	1	669	
EGF-like	670	805	

```

1 atggagattt attccccaga catgtctgag gttagctggcg ggaggtcctc
51 cagcccctcc actcagctga gtgcagcccc atctcttgat gggcttccgg
101 cagcggagga acatatacca gacaccacac cagaagatga gagaagcctc
151 ggactcctgg gcctggcggg gccctgctgt gtgtgcctgg aagctgagcg
201 cctgagaggg tgtctcaact ccgagaagat ctgcattggt cccattctgg
251 cttgcctagt cagcctctgc ctctgcattg ctggcctgaa gtgggtattt
301 gtggacaaga tatttgaata cgactctcct acccacctg accctggggg
351 gttaggccag gaccctgtga tttctctgga tccaactgct gccccagcca
401 ttttggatc atctgaggca tacacttcac ctgtctctaa ggctcagtct
451 gaagctgggg ctcatgttac agtacaaggt gaccatgctg ctgtggcctc
501 tgaaccttca gcagtaccga cccggaagaa ccggctgtct gcttttctc
551 cctttcactc tactgcaccg cccttccctt ctccagctcg gaccctgag
601 gtgagaacac ccaagtcagg aactcagcca caaacaacag aaactaacct
651 gcaaaactgct cctaaacttt ccacatcgac atccacgact gggaccagcc
701 atctcataaa gtgocgggag aaggagaaaa ctttctgtgt gaatgggggc
751 gagtgcttca cgggtgaagga cctgtcaaac ccgtcaagat acttgtgcaa
801 gtgcccaaat gagtttactg gtgatcgttg ccaaaactac gtaatggcca
851 gcttctaca gcatcttggg attgaattta tggaaagcga ggaactctac
901 cagaagaggg tgcctgacaat tactggcatc tgatogccc tgctggtggt
951 cggcatcatg tgtgtggtgg cctactgcaa aaccaagaag cagcggcaga
1001 accttcacga tggcctcagg cagactcttc ggtcagaacc gaccacactc
    
```



Question 3

Correct

Mark 3.0 out of 3.0



You have to amplify ALL the following sequence, from the first to the last nucleotide; please design the FORWARD (=SENSE) primer, 10 base long and the REVERSE (=ANTISENSE) primer, 10 base long;

5' -TGCTATCTGCATGCTTAAGGCGCTAGGCTGACCTGAATCGTAGGCTAGCTAGCTAGCTAGCTCAGATAACCT-3
3' -ACGATAGACGTACGAATTCCGCGATCCGACTGGACTTAGCATCCGATCGATCGATCGATCGAGTCTATTGGA-5'

write only nucleotides, not symbols or numbers.

sense:

antisense:

Question 3

Correct

Mark 3.0 out of 3.0



You have to amplify ALL the following sequence, from the first to the last nucleotide; please design the FORWARD (=SENSE) primer, 10 base long and the REVERSE (=ANTISENSE) primer, 10 base long;

5' -TGCTATCTGCATGCTTAAGGCGCTAGGCTGACCTGAATCGTAGGCTAGCTAGCTAGCTAGCTCAGATAACCT-3'
3' -ACGATAGACGTACGAATTCCGCGATCCGACTGGACTTAGCATCCGATCGATCGATCGATCGAGTCTATTGGA-5'

write only nucleotides, not symbols or numbers.

sense: ✓

antisense: ✓

PROJECT OVERVIEW

Genebank sequence analysis

↓
primer design







↓
RT-PCR







↓
cloning in the vector pCRII-blunt


↓
sequence analysis

subcloning in
different
expression
vectors


- real time PCR
- protein quantification













The internal ribosome entry site (**IRES**) of the encephalomyocarditis virus (ECMV), permits the translation of two open reading frames from one messenger RNA.










Which is the difference among the recombinant proteins obtained with these three expression vectors?






PROTEIN OF INTEREST
EGFP

wooclap




PROTEIN OF INTEREST
EGFP



PROTEIN OF INTEREST
FLAG



PROTEIN OF INTEREST
HA




PROTEIN OF INTEREST
PUROMYCIN RESISTANCE


RT-PCR amplification

- 1 - to clone the **full length cDNA** to express the protein
- 2 -to verify/quantify the **expression of a gene/specific isoform**


1 – where do you put primers if you want to amplify & clone the full length cDNA to express the corresponding full length protein ?



1 – where do you put primers if you want to amplify & clone the full length cDNA to express the corresponding full length protein ?




2 – where do you put primers if you want to verify & quantify the expression of a gene?




Only for teaching purposes - not for reproduction or sale

2 – where do you put primers if you want to verify & quantify the expression of a gene?




Only for teaching purposes - not for reproduction or sale

2 – where do you put primers if you want to verify & quantify the expression of a gene?




Only for teaching purposes - not for reproduction or sale

- sometime you have genomic DNA contamination.
- How can you amplify only cDNA and not contaminant genomic DNA?




1- one strategy could be to design primers on different exons separated by a big intron (≥ 1000 bp)





Only for teaching purposes - not for reproduction or sale


- which strategy could you use if intron is too small (<1000bp)?



- which strategy could you use if intron is too small (<1000bp)?




2 - if introns are too small (< 1000 bp) a good strategy could be to design primers across two exons




Only for teaching purposes - not for reproduction or sale

- what happens if you have a single exon?
- or if you have different isoforms sharing a single exon (and you have to put primers in the same exon to quantify all of them)?




- if you design primers in a single exon, you need to insert a specific control in your experiment, to quantify possible genomic DNA contamination.



- What happen if you have **pseudogenes**?
- What are pseudogenes?

Pseudogenes are cDNA copies inside genomic DNA.

If you have genomic DNA contamination, you can amplify pseudogenes even if your primers are on different exons, separated by a big intron.



Only for teaching purposes - not for reproduction or sale

If you put primers on a single exon or you have pseudogenes, you have to insert a control to quantify genomic DNA contamination.

Which control?

RT


Which control can you do to verify that RNA and the reverse transcription ingredients are not contaminated by DNA (genomic, plasmidic, amplification products)?

	stock	1 sample	RT negative control	final concentration
RNA	0.1 µg/ µl	µl		1 µg/reaction
Buffer	5x	µl		1x
BSA	1 µg/µl	µl		0.1 µg/ µl
Triton	1%	µl		0.05%
dNTPs	10mM	µl		0,5mM
random primers	50 µM	µl		5 µM
RT	100u/µl	µl		200u/reaction
RNAsin	33u/µl	µl		33u/reaction
Water to 25µl		µl		
Tot		25 µl	25 µl	


Only for teaching purposes - not for reproduction or sale

The negative control is called....

Reverse Transcription




RT on the sample that you have to analyse



control "RT-": all the ingredients, except the reverse transcriptase (RT-) to detect genomic DNA contamination

* **IF** you find contamination, you can insert an extra control with **all ingredients except RNA** to detect contamination due to plasmidic DNA or previous amplification.



Usually this control (reagents, without RNA) is not carried out.

PCR reaction

Which control can you do to verify that the PCR reaction is not contaminated by DNA (plasmidic, amplification products)?


STOCK	RT+	RT -	PCR negative ctr	final conc
cDNA	1 μ l			
5x buffer Taq	μ l			-> 1x
sense primer 10 μ M	μ l			-> 250 nM
antisense primer 10 μ M	μ l			-> 250 nM
100% glycerol	μ l			-> 5%
10mM dNTPs	μ l			-> 100 μ M
Taq polimerase 1u/ul	μ l			-> 1u
H ₂ O	μ l			
total	50 μ l	50 μ l		

PCR reaction

Which control can you do to verify that the PCR reaction is not contaminated by DNA (plasmidic, amplification products)?


STOCK	RT+	RT -	PCR negative ctr	final conc
cDNA	1 μ l RT+	1 μ l RT-		
5x buffer Taq	μ l			-> 1x
sense primer 10 μ M	μ l			-> 250 nM
antisense primer 10 μ M	μ l			-> 250 nM
100% glycerol	μ l			-> 5%
10mM dNTPs	μ l			-> 100 μ M
Taq polimerase 1u/ul	μ l			-> 1u
H ₂ O	μ l			
total	50 μ l	50 μ l		

- #- sample
 - A- RT reaction negative control (RT-)
 - B- PCR reaction negative control
 - C- which control is missing?
- which result do you expect?



PCR for the gene of interest

- #- sample
- A- RT reaction negative control (RT-)
- B- PCR reaction negative control
- C- positive control



PCR for the gene of interest

The positive control for your gene of interest is useful to be sure that the negative results are really negative results and not just PCR technical problems (that is: the primers are working well, the mix is ok).

- which control can you do to verify that the RNA is good and correctly retro-transcribed?


(that is, that the negative results are really negative results and not just technical problems...)

-#- sample


-A- RT reaction negative control (RT-)

-B- PCR reaction negative control

-C- positive control



PCR for the gene of interest




housekeeping gene

-You can amplify an housekeeping gene (TBP, actin, GAPDH,).


-You expect that the housekeeping gene is expressed also by those samples that do not express your gene of interest.

- #- sample
- A- RT reaction negative control (RT-)
- B- PCR reaction negative control
- C- positive control




PCR for the gene of interest

?




PCR for the housekeeping gene


- #- sample
- A- RT reaction negative control (RT-)
- B- PCR reaction negative control
- C- positive control



?




- #- sample
- A- RT reaction negative control (RT-)
- B- PCR reaction negative control
- C- positive control




PCR for the gene of interest

- #- sample
- A- RT reaction negative control (RT-)
- B- PCR reaction negative control
- C- positive control




PCR for the gene of interest

- #- sample
- A- RT reaction negative control (RT-)
- B- PCR reaction negative control
- C- positive control




PCR for the gene of interest

?



PCR for the gene of interest

?



PCR for the gene of interest

?


PCR for the gene of interest

STOCK	Sample #	CTR A	CTR B	CTR C	MIX 4 samples	Conc. finale
cDNA	μl					
5 x buffer Taq	μl					-> 1x
Sense primer gene target 10 μM	μl					-> 200 nM
Antisense primer gene target 10 μM	μl					-> 200 nM
100% glycerol	μl					-> 5%
10mM dNTPs	μl					-> 200 μM
Taq polimerase 1u/ul	μl					-> 1u
H ₂ O	μl					
totale	50 μl					


PCR for the housekeeping gene (HKG)

STOCK	Sample #	CTR A	CTR B	CTR C	MIX 4 samples	Conc. finale
cDNA	μl					
5 x buffer Taq	μl					-> 1x
Sense primer HKG 10 μM	μl					-> 200 nM
Antisense primer HKG 10 μM	μl					-> 200 nM
100% glycerol	μl					-> 5%
10mM dNTPs	μl					-> 200 μM
Taq polimerase 1u/ul	μl					-> 1u
H ₂ O	μl					
totale	50 μl					


Reverse Transcription






RT on the sample that you have to analyse




control “RT-”: all the ingredients, except the reverse transcriptase (RT-)



“positive control”: RT on RNA extracted from a sample expressing the gene of interest

	 1 “RT+”	 2 “RT-”	 3 “control +”		MIX x 3	Final concentration
RNA o H ₂ O	μl		–			1 μg
Buffer 5x	μl					1x
BSA 1 μg/μl	μl					0.1 μg/μl
Triton 1%	μl					0.05%
dNTPs 10mM	μl					0,5mM
Random primers 50μM	μl					5 μM
RT 100u/μl	μl	–				200u/25μl
RNAsin 33u/μl	μl					33u/25μl
water to 25μl	μl					
Total	25 μl	25 μl				


RT-PCR



"RT+"



"RT-"



"control +"

RT

25 μ l

take 1 μ l cDNA and amplify by PCR

1 μ l



1 μ l



1 μ l








PCR

50 μ l



+ 49 μ l mix PCR

PCR

STOCK	 1	 2	 3	 4		MIX x 4	
RT	1 µl #1	1 µl #2	1µl #3	–			
H ₂ O	–	–	–	1 µl			
5 x buffer Pfu	µl						-> 1x
Sense primer 10 µM	µl						-> 200 nM
Antisense primer 10 µM	µl						-> 200 nM
100% glicerolo	µl						-> 5%
10mM dNTPs	µl						-> 200 µM
Taq polimerasi 1u/ul	µl						-> 1u/50µl
H ₂ O	µl						
total	50 µl						



25 μ l
REVERSE TRANSCRIPTION



Exercizes

(as soon as you finish, we will discuss your results)


1-find the length of the intron between domain EGF-like and domain alpha

2-find the length of the intron between domain EGF-like and domain beta


3-find coding exons (number and length) and introns (length) of *Rattus norvegicus* TATA box binding protein (Tbp) mRNA, complete cds (NM_001004198.1) to decide where to design primers.

4-find coding exons (number and length) and introns (length) of *Rattus norvegicus* glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, complete cds (AF106860.2) to decide where to design primer

5-if you still have time, you can start to prepare primers for full length cloning, using annhyb or primer3.



- To design primers on different exons separated by a big intron (≥ 1000 bp) you need to know the exon-intron map and length



- How do you identify exons and introns in the genomic DNA?

BLAST finds regions of similarity between biological sequences. The program compares nucleotide or protein sequences to sequence databases and calculates the statistical significance. [Learn more](#)

NEWS We have added a new function to Primer-BLAST that helps users design primers common for a group of highly similar sequences.
Tue, 29 Sep 2020 12:00:00 EST [More BLAST news...](#)


Web BLAST




Nucleotide BLAST
nucleotide ▶ nucleotide



blastx
translated nucleotide ▶ protein



tblastn
protein ▶ translated nucleotide



Protein BLAST
protein ▶ protein

BLAST Genomes

Search

- Human
- Mouse
- Rat**
- Microbes